The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the ...

New Brunswick, New Jersey-based Johnson & Johnson (JNJ) researches, develops, manufactures, and sells various products in the ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of ...

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

The institutional investor owned 3,686 shares of the company’s stock after purchasing an additional 100 shares during the quarter. Strategic Investment Advisors MI’s holdings in Johnson ...

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year. Yet ...

Johnson & Johnson's financial results are generally steady and consistent. Check out the chart of revenue and net income below. The company's balance sheet is rock solid and has earned it an AAA ...